Ventricular Assist Devices (VAD). Extracorporeal Oxygenation and Coronavirus Disease. Surfactant

PerfWeb #59 – Ventricular Assist Devices (VAD)

– Vanderbilt University Medical Center; Department of CV Surgery: Faculty Forum
Vascular Assist Devices (VADs) are a type of mechanical circulatory device used to treat heart failure. VADs work by assisting your heart in pumping blood to the rest of your body, improving circulation to vital organs. Today’s implantable VADs are smaller, lighter and more durable than earlier VADs, and the wide variety of options allows your physician to choose the most appropriate device for your individual needs.
The HeartMate 3™ assists your heart in pumping blood throughout your body and increasing the supply of oxygen to your organs. Designed with Full MagLev™ flow technology, the HeartMate 3 LVAD helps protect the blood as it flows through the pump. The HeartMate 3 Controller is a small wearable computer that constantly monitors system performance through communication with the implanted LVAD.  It alerts the user to any alarm conditions by activating lights, symbols, sounds, and on-screen messages. An internal back up battery adds an extra layer of protection by providing power to the pump for at least 15 minutes during a power loss. The HeartMate 3 is FDA approved for short term use and is currently Investigational for long term patients.

“Extracorporeal Oxygenation and Coronavirus Disease 2019 Epidemic: Is the Membrane Fail-Safe to Cross Contamination?” – Tammy Sparacino Journal Club
Venovenous extracorporeal membrane oxygenation (ECMO) has been safely used as invasive mechanical respiratory support for almost 40 years. This therapy makes full use of cardiopulmonary bypass (CPB) technologies to take over the respiratory function of the lungs, providing oxygen transport and carbon dioxide removal. Historically, several factors such as the high-risk profile target population, the complex technical management, and the generalized skepticism affected the widespread adoption of this therapy. Hence, ECMO for refractory respiratory failure became a niche resource limited to small numbers of patients.

Surfactant – John Ingram Knowledge Nuggets
#perfusion #VAD #surfactant #ECMO

Faculty:

Jordan Hoffman, MD
Joseph Basha, CCP
Matt Warhoover, CCP
John Ingram, CCP

Get our Perfusion App – https://perfusioneducation.com/perfusion-app/
IV Dosage and Rate Calculator – https://mediweb.us/iv-medication-calculator/